Business
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the "Private Placement").Demonstrating strong investor confidence in BioMark's vision and technology, BioMark secured a USD $2 million investment from a pair of strategic in
About this update from Biomark Diagnostics, Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the "Private Placement").","length":372,"tagName":"p"},{"type":"text","content":"Demonstrating strong investor confidence in BioMark's vision and technology, BioMark secured a USD $2 million investment from a pair of strategic investors based in the United States. This substantial investment underscores these investors' strong conviction in BioMark's innovative technology, experienced management team, and proven ability to achieve key milestones with efficient use of capital.","length":411,"tagName":"p"},{"type":"text","content":"Key Highlights of Strategic US Investment:","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Under the first tranche, BioMark issued 9,610,000 units (the "Units") at a price of CAD $0.30 per Unit, for aggregate gross proceeds of CAD $2,883,000.","length":161,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Each unit consists of one common share of BioMark and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at CAD $0.50 per share for a period of three years from the closing date of the private placement.","length":284,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":284,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"The Warrants under the second tranche may be subject to an acceleration clause if the closing trading price of BioMark's shares is greater than CAD $2.50 per common share for a period of 10 consecutive trading days (the "Acceleration Event"). BioMark may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 90 days following the date of such written notice.","length":441,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":441,"olType":false},{"type":"list"...